◀ Back to EGFR
EGFR — YBX1
Text-mined interactions from Literome
Wu et al., Cancer Res 2006
(Breast Neoplasms) :
Disruption of the
Y-box binding protein-1 results in suppression of the
epidermal growth factor receptor and HER-2 ... It was inversely linked to the estrogen receptor ( P < 0.001, r = -0.291 ). Overexpression of
YB-1 in a breast cancer cell line
increased HER-2 and
EGFR. Alternatively, mutation of YB-1 at Ser ( 102 ) > Ala ( 102 ) prevented the induction of these receptors and rendered the cells less responsive to EGF
To et al., Mol Pharmacol 2007
(Breast Neoplasms) :
We reported that
EGFR expression is
induced by the oncogenic transcription factor
Y-box binding protein-1 (YB-1) that occurs in a manner dependent on phosphorylation by Akt
Stratford et al., Breast Cancer Res 2007
(Breast Neoplasms) :
Epidermal growth factor receptor (EGFR) is transcriptionally
induced by the
Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy ... We pursued this in light of our recent work showing that
YB-1 induces the expression of
EGFR , a new BLBC marker ... We determined the regulatory
role of
Y-box binding protein-1 (YB-1) on
epidermal growth factor receptor (EGFR) overexpression in BLBC, and the therapeutic potential of inhibiting EGFR
Kashihara et al., J Thorac Oncol 2009
(Carcinoma, Non-Small-Cell Lung...) :
In the five NSCLC cell lines, expressions of
EGFR , human epidermal growth factor receptor 2 ( HER2 ), HER3, and hepatocyte growth factor receptor ( c-Met ) in PC-9 cells ; of HER2 and c-Met in EBC-1 cells ; and of HER3 in QG56 cells were
down-regulated by
YB-1 knockdown
Xie et al., Tumour Biol 2012
(Breast Neoplasms) :
The expression of
YB-1 in the nucleus of breast cancer cells positively correlated with the Scarff-Bloom-Richardson grade ( P = 0.007 ) and HER-2 expression ( P = 0.005 ), negatively correlated with ER expression ( P = 0.004 ), and was
independent of the age, menstrual status, pathological type, tumor size, lymph node status, presence of thrombosis, PR expression, and
EGFR expression